Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Phyllis Fiveash

Nurse Practitioner, Family Corinth, MS Nurse Practitioner

NPI 1689996282 CMS profile 76863

2001 State Dr, Corinth, MS 38834

Open in the dashboard

General payments

$11,618

608 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Phyllis Fiveash of Corinth, MS is reported in the CMS Open Payments database as having received $11,618 across 608 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,221 103
2024 General $2,414 116
2023 General $2,562 137
2022 General $2,044 111
2021 General $2,377 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phyllis Fiveash
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Phyllis Fiveash were reported at $2,221. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Phyllis Fiveash Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,377 $124 $35–$379 $132
2022 $2,044 $141 $44–$430 $149
2023 $2,562 $154 $49–$476 $160
2024 $2,414 $165 $51–$504 $164
2025 $2,221 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $942 48 payments
  2. GlaxoSmithKline, LLC. $886 45 payments
  3. AstraZeneca Pharmaceuticals LP $744 36 payments
  4. Pfizer Inc. $630 31 payments
  5. Novartis Pharmaceuticals Corporation $618 35 payments
  6. Janssen Biotech, Inc. $512 36 payments
  7. Eisai Inc. $463 27 payments
  8. E.R. Squibb & Sons, L.L.C. $438 28 payments
  9. Seattle Genetics, Inc. $429 26 payments
  10. Gilead Sciences, Inc. $379 15 payments
  11. Other $5,576 281 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,386 604 payments
  2. Education $232 4 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $835 43 payments
  2. ZEJULA $553 25 payments
  3. JEMPERLI $486 22 payments
  4. Lenvima $463 27 payments
  5. XTANDI $364 17 payments
  6. REBLOZYL $331 15 payments
  7. OPDIVO $329 22 payments
  8. BRUKINSA $327 18 payments
  9. ORGOVYX $301 14 payments
  10. IMBRUVICA $294 11 payments
  11. Other $9,370 512 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

300

Median for Nurse Practitioner: 389

Drug cost

$25,340

Median for Nurse Practitioner: $21,885

Branded share of claims

29%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $11,847
Xarelto Rivaroxaban Brand 16 $9,937
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 33 $871
Hydroxyurea Generic 29 $757
Potassium Chloride Generic 43 $528
Tamoxifen Citrate Generic 23 $516
Letrozole Generic 19 $260
Ondansetron Hcl Generic 24 $165
Escitalopram Oxalate Generic 23 $164
Ondansetron Odt Ondansetron Brand 18 $138

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 154 billing codes

Paid by Medicare

$1,552,370

Of which drugs: $1,468,844

Medicare patients

682

Average age 73

Services billed

77,733

402 women, 280 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Cancer 43%
Diabetes 40%
COPD 38%
Ischemic heart disease 37%
Depression 35%
Chronic kidney disease 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 16 8,000 $357,706
Injection, denosumab, 1 mg J0897 Office 30 3,240 $67,103
Injection, ferric derisomaltose, 10 mg J1437 Office 29 2,900 $46,347
Injection, eflapegrastim-xnst, 0.1 mg J1449 Office 11 2,244 $45,001
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 Office 13 5,320 $11,547
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 Office 13 15 $8,046
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 33 832 $192
Injection, palonosetron hcl, 25 mcg J2469 Office 14 180 $119
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 47 874 $71
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 27 50 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $212
$212 — —
MONOFERRIC
  • Pharmacosmos Therapeutics Inc. $147
$147 — 2,900
REBLOZYL
  • Celgene Corporation $130
  • Merck Sharp & Dohme Corporation $8
$138 — —
Lenvima
  • Eisai Inc. $122
$122 — —
OJJAARA
  • GlaxoSmithKline, LLC. $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

608 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record